Abstract
Uterine carcinosarcoma (UCS) is a rare and highly aggressive disease, which has been categorized as a subtype of high-grade endometrial cancer but not uterine sarcoma. A high clinical efficacy of a novel anti-HER2 antibody drug conjugate, trastuzumab deruxtecan (T-DXd), in HER2-positive UCS will be reported at ESMO2021 (STATICE TRIAL). Herein, we report a co-clinical study of T-DXd using patient-derived xenograft (PDX) models of patients that participated in the STATICE trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
